Nicole Clark, MD
Neurology · Helena, MTNPI 1689861528
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $51,861 of the $85,144 with a category attached, or 60.9%. 30 manufacturers reported payments, led by Argenx US, Inc. at 47.5% of the total. 2025 is the largest year on record at $27,262, more than ten times the $665 reported in 2019. Among neurology clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 225 payments — averaging $378.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$40K
- Johnson & Johnson$17K
- AbbVie$11K
- Amgen$8K
- Janssen Scientific Affairs, LLC$2K
- Lundbeck LLC$1K
- plus $6K from 24 others
What the payments were for
- Consulting fees$14,73517%
- Speaking & faculty fees$51,86161%
- Travel & lodging$13,29516%
- Food & beverage$5,1426%
- Education$1110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 47 | $40,411 |
| Johnson & Johnson | 17 | $16,801 |
| AbbVie(2 entities) | 19 | $11,486 |
| Amgen | 6 | $7,547 |
| Janssen Scientific Affairs, LLC | 4 | $1,857 |
| Lundbeck LLC | 1 | $1,275 |
| Sanofi | 21 | $1,252 |
| Boston Scientific | 5 | $1,140 |
| Biohaven Pharmaceuticals, Inc. | 1 | $1,125 |
| Biogen | 23 | $377 |
| Livanova USA, Inc. | 8 | $284 |
| Teva Pharmaceuticals USA, Inc. | 7 | $274 |
| Bristol Myers Squibb | 16 | $272 |
| EMD Serono, Inc. | 8 | $224 |
| Genentech USA, Inc. | 10 | $216 |
| Neurocrine Biosciences, Inc. | 8 | $166 |
| Pfizer | 4 | $113 |
| TG Therapeutics, Inc. | 2 | $48 |
| Lilly USA, LLC | 3 | $48 |
| UCB, Inc. | 3 | $42 |
| Jazz Pharmaceuticals Inc. | 2 | $28 |
| Sunovion Pharmaceuticals Inc. | 2 | $25 |
| Abbott | 1 | $22 |
| Acorda Therapeutics, Inc | 1 | $21 |
| Catalyst Pharmaceuticals, Inc. | 1 | $20 |
| AstraZeneca | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Merz Pharmaceuticals, LLC | 1 | $14 |
| Medtronic | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$32,439
- UBRELVY$11,210
- UPLIZNA$7,532
- VYEPTI$1,275
- NURTEC ODT$1,125
- VERCISE$1,122
- AUBAGIO$844
- VYVGART HYTRULO$165
- OCREVUS$115
How this compares
$85,144 in reported general payments places this provider in the 95th percentile of 48 neurology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 40 | $250,810 |
| IngrezzaValbenazine Tosylate | 28 | $235,164 |
| AubagioTeriflunomide | 16 | $147,024 |
| Avonex (4 Pack)Interferon Beta-1a | 13 | $104,422 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 12 | $96,790 |
| GlatopaGlatiramer Acetate | 15 | $46,646 |
| Glatiramer Acetate | 18 | $36,662 |
| BriviactBrivaracetam | 16 | $28,371 |
| Emgality PenGalcanezumab-Gnlm | 31 | $24,341 |
| Aimovig AutoinjectorErenumab-Aooe | 18 | $23,265 |
| Levetiracetam | 505 | $15,755 |
| Teriflunomide | 170 | $15,077 |
| ReyvowLasmiditan Succinate | 15 | $11,924 |
| Carbamazepine ErCarbamazepine | 218 | $10,069 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 103 | $8,966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone | $274 | $250,81040 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $166 | $235,16428 claims |
| SanofiAubagio | $1,252 | $147,02416 claims |
| BiogenAvonex (4 Pack) | $377 | $104,42213 claims |
| UCB, Inc.Briviact | $42 | $28,37116 claims |
| Lilly USA, LLCReyvow | $48 | $11,92415 claims |
| PfizerDilantin | $113 | $5,81025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 48 neurology providers in Montana.
Other neurology in Helena
- Thomas MulgrewHelena$3K
- Mallory EmigHelena$876
- Sylvia RojasHelena$393
- Ann CollierBillings$164K
- Dennis DietrichGreat Falls$140K
- Kristian FrenchBillings$64K
- Norman FriedmanKalispell$35K
- Deborah DoverGreat Falls$19K
- Eliad CulceaGreat Falls$19K
- Emily PharrBozeman$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.